Middle East and Africa Hereditary Cancer Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Hereditary Cancer Testing Market Size

• The Middle East and Africa hereditary cancer testing market size was valued at USD 236.59 million in 2025 and is expected to reach USD 553.13 million by 2033, at a CAGR of 11.2% during the forecast period
• The market growth is largely fueled by the increasing prevalence of cancer across the region, rising awareness regarding genetic risk factors, and the expanding adoption of advanced diagnostic technologies such as next-generation sequencing (NGS), supporting improved early detection and precision medicine initiatives
• Furthermore, growing investments in healthcare infrastructure, government-led genomics programs, and the rising demand for personalized and preventive healthcare solutions are establishing hereditary cancer testing as a critical component of modern diagnostics in both emerging and developed MEA economies, thereby significantly boosting the market’s growth trajectory

Middle East and Africa Hereditary Cancer Testing Market Analysis

• Hereditary cancer testing, involving genetic analysis to identify inherited cancer risks such as BRCA and Lynch syndrome mutations, is becoming an essential component of modern diagnostics and preventive healthcare systems across both developed and emerging countries in the Middle East and Africa due to its role in early detection, risk assessment, and personalized treatment planning
• The escalating demand for hereditary cancer testing is primarily fueled by the rising incidence of cancer, increasing awareness about genetic predisposition, and a growing preference for precision medicine and early intervention strategies among patients and healthcare providers
• Saudi Arabia dominated the market with the largest revenue share of 34.8% in 2025, characterized by improving healthcare infrastructure, strong government initiatives in genomics, and increasing adoption of advanced diagnostic technologies, with significant growth in genetic testing services supported by national screening programs and public-private investments
• South Africa is expected to be the fastest growing country in the hereditary cancer testing market during the forecast period due to expanding healthcare access, increasing collaborations with international diagnostic companies, and growing efforts to enhance cancer awareness and screening programs
• Sequencing segment dominated the hereditary cancer testing market with a market share of 58.6% in 2025, driven by its high accuracy, capability to analyze multiple genes simultaneously, and increasing adoption in clinical laboratories for comprehensive and efficient cancer risk assessment

Report Scope and Middle East and Africa Hereditary Cancer Testing Market Segmentation

Middle East and Africa Hereditary Cancer Testing Market Trends

“Rising Adoption of Genomic Technologies and Personalized Medicine”

• A significant and accelerating trend in the Middle East and Africa hereditary cancer testing market is the increasing integration of advanced genomic technologies such as next-generation sequencing (NGS) and bioinformatics platforms into routine clinical practice. This convergence of technologies is significantly enhancing diagnostic accuracy and early detection capabilities
• For instance, several regional laboratories are adopting multi-gene panel testing solutions that enable simultaneous screening of multiple cancer-associated mutations, improving efficiency and turnaround time for patients. Similarly, healthcare providers are leveraging digital platforms to streamline genetic counseling and reporting processes
• Integration of advanced sequencing technologies enables features such as comprehensive mutation profiling, identification of rare genetic variants, and improved risk stratification for patients. For instance, some laboratories utilize AI-supported analytics to enhance interpretation accuracy and provide actionable insights for clinicians. Furthermore, digital health integration allows seamless sharing of patient data, enabling better clinical decision-making and coordinated care
• The seamless integration of hereditary cancer testing with broader healthcare systems facilitates centralized patient management and improved accessibility to diagnostic services. Through unified platforms, healthcare providers can coordinate screening, diagnosis, and treatment planning, creating a more efficient and patient-centric care pathway
• This trend towards more precise, data-driven, and interconnected diagnostic systems is fundamentally reshaping patient care approaches in oncology. Consequently, companies such as Illumina are advancing sequencing technologies with enhanced accuracy and scalability for hereditary cancer testing applications
• The demand for hereditary cancer testing solutions that offer high accuracy, scalability, and integration with digital health systems is growing rapidly across both public and private healthcare sectors, as stakeholders increasingly prioritize early detection and personalized treatment strategies
• In addition, the growing focus on preventive healthcare and population-level genetic screening initiatives is expanding the adoption of hereditary cancer testing as part of routine health check-ups and national cancer control strategies

Middle East and Africa Hereditary Cancer Testing Market Dynamics

Driver

“Growing Need Due to Rising Cancer Burden and Expansion of Precision Medicine”

• The increasing prevalence of cancer cases across the Middle East and Africa, coupled with the expanding adoption of precision medicine initiatives, is a significant driver for the heightened demand for hereditary cancer testing
• For instance, in recent years, governments in countries such as Saudi Arabia and United Arab Emirates have launched national genomics programs aimed at improving early detection and personalized treatment, supporting the growth of genetic testing services. Such strategies by key stakeholders are expected to drive the hereditary cancer testing market growth in the forecast period
• As awareness regarding genetic predisposition to cancer increases, patients and healthcare providers are increasingly adopting testing solutions that offer early risk identification and preventive care options, providing a compelling shift from traditional diagnostic approaches
• Furthermore, the growing investment in healthcare infrastructure and the rising availability of advanced diagnostic technologies are making hereditary cancer testing an integral component of modern oncology care, offering seamless integration with treatment planning and monitoring systems
• The ability to identify at-risk individuals, guide targeted therapies, and improve clinical outcomes through genetic insights are key factors propelling the adoption of hereditary cancer testing across both public and private healthcare sectors. The expansion of diagnostic laboratories and increasing collaborations with global companies further contribute to market growth
• Rising government funding and policy support for cancer research and genomics programs are further strengthening the ecosystem for hereditary cancer testing adoption across the region
• Increasing penetration of private healthcare providers and diagnostic chains is also enhancing accessibility and availability of advanced genetic testing services, thereby supporting market expansion

Restraint/Challenge

“Limited Awareness and High Cost of Advanced Genetic Testing”

• Limited awareness regarding hereditary cancer testing and its benefits, particularly in underdeveloped regions of Africa, poses a significant challenge to broader market penetration. In addition, the high cost of advanced genetic testing technologies remains a key barrier for widespread adoption
• For instance, disparities in healthcare access and limited availability of specialized genetic counseling services in several African countries have restricted the adoption of hereditary cancer testing, slowing market growth in these regions
• Addressing these challenges through increased awareness campaigns, training of healthcare professionals, and expansion of testing facilities is crucial for improving adoption rates. Companies such as F. Hoffmann-La Roche Ltd emphasize affordability initiatives and partnerships to expand access to diagnostic solutions. In addition, the complexity of genetic data interpretation and lack of skilled professionals can hinder effective implementation in certain regions
• While technological advancements are improving testing capabilities, the affordability gap and infrastructure limitations continue to restrict accessibility, especially for low-income populations. Concerns related to data privacy and ethical considerations surrounding genetic testing also contribute to hesitancy among potential users
• Overcoming these challenges through policy support, cost reduction strategies, and increased collaboration between public and private sectors will be vital for sustained market growth in the Middle East and Africa hereditary cancer testing market
• Limited reimbursement policies and lack of insurance coverage for genetic testing in several countries further restrict patient access and affordability, slowing overall market adoption
• In addition, logistical challenges such as sample transportation, limited laboratory infrastructure, and uneven distribution of healthcare resources across rural areas continue to hinder widespread implementation of hereditary cancer testing services

Middle East and Africa Hereditary Cancer Testing Market Scope

The market is segmented on the basis of test type, diagnosis type, technology, disease type, end user, and distribution channel.

• By Test Type

On the basis of test type, the Middle East and Africa hereditary cancer testing market is segmented into multi panel set and single site genetic test. The multi panel set segment dominated the market with the largest market revenue share in 2025, driven by its ability to analyze multiple cancer-related genes simultaneously, improving diagnostic efficiency and accuracy. Healthcare providers increasingly prefer multi-gene panels as they offer comprehensive insights into hereditary cancer risks within a single test. These panels are particularly valuable in identifying complex genetic mutations across different syndromes, reducing the need for multiple individual tests. In addition, advancements in sequencing technologies have made multi panel testing more accessible and cost-effective. The growing demand for precision medicine and personalized treatment approaches further supports the dominance of this segment.

The single site genetic test segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by its targeted approach in detecting specific known mutations within families. These tests are highly effective for individuals with a confirmed family history of particular genetic mutations, offering cost-efficient and rapid results. Increasing awareness about inherited cancer risks is encouraging individuals to opt for targeted screening solutions. Furthermore, healthcare providers are utilizing single site tests for follow-up and confirmatory diagnostics. The affordability and simplicity of these tests compared to broader panels are also contributing to their rising adoption across emerging healthcare settings.

• By Diagnosis Type

On the basis of diagnosis type, the market is segmented into biopsy, imaging, and lab tests. The lab tests segment dominated the market with the largest revenue share in 2025, driven by the essential role of genetic and molecular testing in confirming hereditary cancer risks. Laboratory-based diagnostics, including blood and saliva tests, provide accurate and reliable genetic information required for early detection. These tests are widely used due to their non-invasive nature and compatibility with advanced genomic technologies. The expansion of diagnostic laboratories across the region has further strengthened this segment. In addition, increasing adoption of molecular diagnostics and biomarker-based testing is boosting demand for lab-based solutions.

The imaging segment is expected to witness the fastest growth rate during the forecast period, driven by its complementary role in identifying and monitoring cancer development in high-risk individuals. Advanced imaging technologies are increasingly integrated with genetic testing to provide a comprehensive diagnostic approach. Growing investments in radiology infrastructure and improved accessibility to imaging services are supporting segment growth. Healthcare providers are leveraging imaging tools for early-stage cancer detection and surveillance in genetically predisposed patients. The rising adoption of combined diagnostic strategies is further accelerating the demand for imaging solutions.

• By Technology

On the basis of technology, the market is segmented into sequencing, polymerase chain reaction (PCR), and microarray. The Sequencing segment dominated the market with the largest revenue of 58.6% share in 2025, driven by its high accuracy and ability to analyze multiple genes simultaneously. Sequencing technologies, particularly next-generation sequencing (NGS), enable comprehensive detection of genetic mutations associated with hereditary cancers. These technologies are widely adopted in clinical laboratories due to their scalability and efficiency. The declining cost of sequencing and advancements in bioinformatics tools have further enhanced their accessibility. In addition, sequencing supports personalized medicine by providing detailed genomic insights for targeted therapies.

The polymerase chain reaction (PCR) segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by its rapid turnaround time and cost-effectiveness for targeted mutation analysis. PCR-based techniques are widely used for detecting specific genetic alterations, making them suitable for routine diagnostics and follow-up testing. The simplicity and reliability of PCR methods contribute to their growing adoption in resource-limited settings. Increasing demand for quick and accurate diagnostic solutions is further driving this segment. Moreover, ongoing technological improvements in PCR platforms are enhancing sensitivity and expanding their application scope.

• By Disease Type

On the basis of disease type, the market is segmented into hereditary breast & ovarian cancer syndrome, Cowden syndrome, Lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), Li-Fraumeni syndrome, von Hippel-Lindau disease, and multiple endocrine neoplasias (MEN) syndromes. The hereditary breast & ovarian cancer syndrome segment dominated the market with the largest revenue share in 2025, driven by the high prevalence of BRCA1 and BRCA2 gene mutations. Increasing awareness campaigns and screening programs focused on breast cancer are significantly boosting testing rates. Healthcare providers prioritize this segment due to its strong association with early detection and preventive care strategies. The availability of targeted therapies further enhances the importance of accurate genetic diagnosis. In addition, rising adoption of preventive testing among high-risk populations supports segment dominance.

The Lynch syndrome segment is expected to witness the fastest growth rate during the forecast period, driven by increasing recognition of its association with colorectal and other cancers. Growing awareness among healthcare professionals and patients is leading to higher screening rates. Advances in genetic testing technologies are enabling more accurate identification of Lynch syndrome mutations. Early diagnosis plays a critical role in preventing cancer progression, further supporting demand. In addition, expanding screening guidelines and initiatives are accelerating adoption in this segment.

• By End User

On the basis of end user, the market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others. The hospitals segment dominated the market with the largest revenue share in 2025, driven by the availability of advanced diagnostic infrastructure and skilled healthcare professionals. Hospitals serve as primary centers for cancer diagnosis and treatment, integrating genetic testing into patient care pathways. The presence of multidisciplinary teams enables comprehensive evaluation and management of hereditary cancer risks. Increasing patient inflow and government investments in hospital infrastructure further strengthen this segment. In addition, hospitals often collaborate with diagnostic companies to offer advanced testing services.

The diagnostic centers segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing demand for specialized and cost-effective testing services. Diagnostic centers offer dedicated genetic testing solutions with faster turnaround times compared to traditional healthcare facilities. The expansion of private diagnostic chains across the region is enhancing accessibility to advanced testing. Patients are increasingly opting for these centers due to convenience and affordability. Furthermore, technological advancements and partnerships with global companies are supporting segment growth.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender and retail sales. The direct tender segment dominated the market with the largest revenue share in 2025, driven by bulk procurement of testing kits and services by hospitals, government institutions, and large healthcare organizations. Direct tenders ensure cost efficiency and consistent supply of diagnostic solutions for large-scale screening programs. Governments and public health agencies often rely on this channel for implementing national cancer screening initiatives. The structured procurement process also supports quality assurance and regulatory compliance. In addition, partnerships between manufacturers and healthcare providers further strengthen this segment.

The retail sales segment is expected to witness the fastest growth rate during the forecast period, driven by increasing availability of genetic testing kits through private channels and online platforms. Rising consumer awareness and demand for at-home testing solutions are contributing to segment growth. Retail channels provide easy access and convenience for individuals seeking preventive healthcare options. The expansion of e-commerce platforms is further enhancing product availability across the region. Moreover, the growing trend of personalized healthcare is encouraging consumers to adopt direct-to-consumer genetic testing solutions.

Middle East and Africa Hereditary Cancer Testing Market Regional Analysis

• Saudi Arabia dominated the market with the largest revenue share of 34.8% in 2025, characterized by improving healthcare infrastructure, strong government initiatives in genomics, and increasing adoption of advanced diagnostic technologies, with significant growth in genetic testing services supported by national screening programs and public-private investments
• Healthcare providers and patients in the country highly value the accuracy, early risk identification, and personalized treatment insights offered by hereditary cancer testing solutions, along with their integration into broader oncology care pathways
• This growing adoption is further supported by improving healthcare infrastructure, rising government investments in genomics programs, and increasing awareness about genetic testing, establishing hereditary cancer testing as a critical component of modern diagnostics across both public and private healthcare systems

The Saudi Arabia Hereditary Cancer Testing Market Insight

The Saudi Arabia hereditary cancer testing market captured the largest revenue share of 34.8% in 2025 within the Middle East and Africa, fueled by the increasing prevalence of cancer and the expansion of national genomics initiatives. Healthcare providers are increasingly prioritizing early detection and personalized treatment through advanced genetic testing solutions. The growing preference for preventive healthcare, combined with strong government support and investments in precision medicine, further propels the hereditary cancer testing industry. Moreover, the integration of advanced sequencing technologies and digital health platforms is significantly contributing to the market's expansion.

United Arab Emirates Hereditary Cancer Testing Market Insight

The UAE hereditary cancer testing market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the increasing adoption of advanced healthcare technologies and a strong focus on preventive medicine. In addition, rising awareness about inherited cancer risks is encouraging individuals and healthcare providers to opt for genetic testing solutions. The UAE’s emphasis on healthcare innovation, alongside its expanding network of private healthcare providers and diagnostic centers, is expected to continue to stimulate market growth.

South Africa Hereditary Cancer Testing Market Insight

The South Africa hereditary cancer testing market is expected to expand at a considerable CAGR during the forecast period, fueled by improving healthcare infrastructure and increasing awareness of genetic testing. The country’s growing focus on early cancer detection, combined with collaborations with international diagnostic companies, promotes the adoption of hereditary cancer testing, particularly in urban healthcare settings. The integration of genetic testing into oncology services is also becoming increasingly prevalent, with a strong emphasis on improving accessibility and affordability for patients.

Egypt Hereditary Cancer Testing Market Insight

The Egypt hereditary cancer testing market is gaining momentum due to the country’s improving healthcare infrastructure, rising cancer incidence, and increasing awareness regarding genetic testing. The market places a significant emphasis on early diagnosis, and the adoption of hereditary cancer testing is driven by the growing number of diagnostic laboratories and oncology centers. The integration of genetic testing with broader healthcare services is fueling growth. Moreover, Egypt’s expanding population and healthcare reforms are likely to spur demand for accessible and cost-effective testing solutions in both public and private sectors.

Middle East and Africa Hereditary Cancer Testing Market Share

The Middle East and Africa Hereditary Cancer Testing industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd (Switzerland)
• QIAGEN (Netherlands)
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• Danaher (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Eurofins Scientific (Luxembourg)
• Myriad Genetics, Inc. (U.S.)
• Invitae Corporation (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Fulgent Genetics, Inc. (U.S.)
• Natera, Inc. (U.S.)
• Exact Sciences Corporation (U.S.)
• Guardant Health, Inc. (U.S.)
• BGI Genomics Co., Ltd. (China)
• Macrogen, Inc. (South Korea)
• MedGenome Labs Ltd. (India)
• Strand Life Sciences Pvt Ltd (India)

What are the Recent Developments in Middle East and Africa Hereditary Cancer Testing Market?

• In April 2025, the Department of Health in United Arab Emirates announced a strategic partnership to advance precision medicine and genomic healthcare innovation. The collaboration focuses on expanding genetic testing capabilities, including hereditary cancer diagnostics, and strengthening the region’s position in personalized medicine and early disease detection
• In January 2025, Dubai Health in United Arab Emirates expanded its genomics capabilities and doubled testing capacity to support nationwide genetic screening programs. The initiative includes large-scale next-generation sequencing (NGS) and enhanced genetic counseling services, aimed at improving early detection of hereditary diseases and advancing precision medicine across the country
• In April 2024, SOPHiA GENETICS partnered with Syndicate Bio to introduce comprehensive genomic profiling and liquid biopsy services across Africa. This collaboration aims to expand access to advanced cancer diagnostics, including hereditary cancer testing, by leveraging AI-driven analytics and next-generation sequencing technologies to improve early detection and precision oncology outcomes
• In April 2024, global sequencing laboratories and advocacy groups partnered to expand access to genetic testing services worldwide, including the Middle East and Africa. The initiative focuses on improving availability of hereditary cancer testing through collaborative efforts in sequencing infrastructure, education, and clinical adoption, strengthening precision medicine capabilities in underserved regions
• In January 2024, Guardant Health partnered with Hikma Pharmaceuticals to expand access to comprehensive genomic profiling and liquid biopsy-based cancer tests across the Middle East and North Africa. The collaboration enables broader availability of next-generation sequencing (NGS) solutions for cancer screening, recurrence monitoring, and treatment selection, significantly enhancing hereditary cancer testing capabilities and precision oncology adoption in the region

SKU-69433